|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RSBN1L |
Gene summary for RSBN1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RSBN1L | Gene ID | 222194 |
| Gene name | round spermatid basic protein 1 like | |
| Gene Alias | RSBN1L | |
| Cytomap | 7q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6PCB5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 222194 | RSBN1L | LZE2D | Human | Esophagus | HGIN | 1.28e-02 | 2.34e-01 | 0.0642 |
| 222194 | RSBN1L | LZE2T | Human | Esophagus | ESCC | 3.77e-05 | 6.56e-01 | 0.082 |
| 222194 | RSBN1L | LZE3D | Human | Esophagus | HGIN | 8.67e-04 | 8.71e-01 | 0.0668 |
| 222194 | RSBN1L | LZE4T | Human | Esophagus | ESCC | 2.29e-16 | 4.82e-01 | 0.0811 |
| 222194 | RSBN1L | LZE7T | Human | Esophagus | ESCC | 7.55e-17 | 9.59e-01 | 0.0667 |
| 222194 | RSBN1L | LZE8T | Human | Esophagus | ESCC | 9.21e-04 | 2.53e-01 | 0.067 |
| 222194 | RSBN1L | LZE20T | Human | Esophagus | ESCC | 1.53e-14 | 3.86e-01 | 0.0662 |
| 222194 | RSBN1L | LZE22D1 | Human | Esophagus | HGIN | 1.01e-10 | 4.21e-01 | 0.0595 |
| 222194 | RSBN1L | LZE22T | Human | Esophagus | ESCC | 2.45e-10 | 6.75e-01 | 0.068 |
| 222194 | RSBN1L | LZE24T | Human | Esophagus | ESCC | 5.64e-21 | 5.75e-01 | 0.0596 |
| 222194 | RSBN1L | LZE22D3 | Human | Esophagus | HGIN | 3.47e-04 | 5.17e-01 | 0.0653 |
| 222194 | RSBN1L | LZE21T | Human | Esophagus | ESCC | 2.86e-11 | 6.24e-01 | 0.0655 |
| 222194 | RSBN1L | LZE6T | Human | Esophagus | ESCC | 2.37e-08 | 2.52e-01 | 0.0845 |
| 222194 | RSBN1L | P1T-E | Human | Esophagus | ESCC | 1.15e-22 | 1.13e+00 | 0.0875 |
| 222194 | RSBN1L | P2T-E | Human | Esophagus | ESCC | 1.13e-51 | 9.26e-01 | 0.1177 |
| 222194 | RSBN1L | P4T-E | Human | Esophagus | ESCC | 1.96e-41 | 1.01e+00 | 0.1323 |
| 222194 | RSBN1L | P5T-E | Human | Esophagus | ESCC | 1.14e-33 | 5.66e-01 | 0.1327 |
| 222194 | RSBN1L | P8T-E | Human | Esophagus | ESCC | 1.25e-35 | 7.34e-01 | 0.0889 |
| 222194 | RSBN1L | P9T-E | Human | Esophagus | ESCC | 8.18e-39 | 9.43e-01 | 0.1131 |
| 222194 | RSBN1L | P10T-E | Human | Esophagus | ESCC | 6.77e-67 | 1.16e+00 | 0.116 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RSBN1L | SNV | Missense_Mutation | rs202084915 | c.1294T>G | p.Leu432Val | p.L432V | Q6PCB5 | protein_coding | deleterious(0.02) | possibly_damaging(0.607) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| RSBN1L | SNV | Missense_Mutation | rs202084915 | c.1294T>G | p.Leu432Val | p.L432V | Q6PCB5 | protein_coding | deleterious(0.02) | possibly_damaging(0.607) | TCGA-A2-A0CV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| RSBN1L | SNV | Missense_Mutation | rs202084915 | c.1294N>G | p.Leu432Val | p.L432V | Q6PCB5 | protein_coding | deleterious(0.02) | possibly_damaging(0.607) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| RSBN1L | SNV | Missense_Mutation | rs778847628 | c.1742G>A | p.Arg581Gln | p.R581Q | Q6PCB5 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RSBN1L | SNV | Missense_Mutation | novel | c.1865G>A | p.Arg622Gln | p.R622Q | Q6PCB5 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RSBN1L | SNV | Missense_Mutation | rs202084915 | c.1294N>G | p.Leu432Val | p.L432V | Q6PCB5 | protein_coding | deleterious(0.02) | possibly_damaging(0.607) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| RSBN1L | SNV | Missense_Mutation | rs202084915 | c.1294N>G | p.Leu432Val | p.L432V | Q6PCB5 | protein_coding | deleterious(0.02) | possibly_damaging(0.607) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD |
| RSBN1L | SNV | Missense_Mutation | rs202084915 | c.1294N>G | p.Leu432Val | p.L432V | Q6PCB5 | protein_coding | deleterious(0.02) | possibly_damaging(0.607) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| RSBN1L | SNV | Missense_Mutation | rs202084915 | c.1294N>G | p.Leu432Val | p.L432V | Q6PCB5 | protein_coding | deleterious(0.02) | possibly_damaging(0.607) | TCGA-B6-A0WS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RSBN1L | SNV | Missense_Mutation | rs202084915 | c.1294T>G | p.Leu432Val | p.L432V | Q6PCB5 | protein_coding | deleterious(0.02) | possibly_damaging(0.607) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |